header-news

Latest News

Formal Agreement Reached for $900 Million Sale of Pharmaceuticals Division to Aspen Pharmacare

November 22, 2010

On 16 August 2010, Sigma announced that it had agreed in principle to sell its Pharmaceuticals Division to the Aspen Pharmacare Holdings Limited group of companies for A$900 million.

Read More >>

Aspen to distribute Merck products

October 7, 2010

Effective immediately, Aspen is taking over the sales, distribution and marketing of a portfolio of dermatology products from Merck, with estimated annual sales of $50 million.

Read More >>

Stephen Saad, CEO of Aspen Holdings, comments on Sigma purchase

August 17, 2010

An interview of Stephen Saad, CEO of Aspen Holdings.

Read More >>

Aspen Announcement to JSE

August 16, 2010

Announcement regarding the acquisition of the pharmaceutical business of Sigma Pharmaceuticals Limited by Aspen.

Read More >>

Aspen make a bid for Sigma

May 24, 2010

Aspen shareholders are advised that Aspen has submitted an indicative non-binding proposal to acquire, either directly or through a wholly-owned subsidiary, Sigma Pharmaceuticals Limited.

Read More >>

Aspen and GSK Agree On Series Of Strategic Transactions

May 13, 2009

Aspen, Africa’s largest pharmaceutical manufacturer, has announced that it has agreed to multiple, strategic, inter-dependent transactions with a leading multinational pharmaceutical group, GlaxoSmithKline.

Read More >>

Diversity and Flexibility eNews

April 29, 2009

Aspen’s high level of flexibility has shown demonstrable business outcomes in addition to the attraction/retention of diverse talent, including consistently meeting sales objectives and extremely high value customer relationships.

Read More >>

Aspen take on Tritace and Cardizem

March 6, 2008

Aspen Pharmacare have signed a licensing agreement with Sanofi-Aventis for the distribution, sales and marketing of Tritace and Cardizem.

Read More >>

Aspen form alliance with Actavis

March 6, 2008

Aspen Australia have signed a license agreement with Actavis, taking on the sales, marketing and distribution of two products, Neotigason and Rapilysin.

Read More >>